perience higher rates of acute rejection compared to patients treated with conventional immunosuppression. Costimulation blockade-resistant rejection (CoBRR) is associated with terminally differentiated T cells. Alemtuzumab induction and belatacept/sirolimus immunotherapy effectively prevent CoBRR. We hypothesized that cells in late phases of differentiation would be selectively less capable than more naive phenotypes of repopulating postdepletion, providing a potential mechanism by which lymphocyte depletion and repopulation could reduce the risk of CoBRR.
Kidney transplant patients treated with belatacept without depletional induction experience higher rates of acute rejection compared to patients treated with conventional immunosuppression. Costimulation blockade-resistant rejection (CoBRR) is associated with terminally differentiated T cells. Alemtuzumab induction and belatacept/sirolimus immunotherapy effectively prevent CoBRR. We hypothesized that cells in late phases of differentiation would be selectively less capable than more naive phenotypes of repopulating postdepletion, providing a potential mechanism by which lymphocyte depletion and repopulation could reduce the risk of CoBRR.
Lymphocytes from 20 recipients undergoing alemtuzumab-induced depletion and belatacept/sirolimus immunosuppression were studied longitudinally for markers of maturation (CCR7, CD45RA, CD57, PD1), recent thymic emigration (CD31), and the IL-7 receptor-α (IL-7Rα). Serum was analyzed for IL-7. Alemtuzumab induction produced profound lymphopenia followed by repopulation, during which naive IL- 
| INTRODUCTION
Calcineurin inhibitor (CNI)-based conventional immunotherapy nonspecifically inhibits naive and memory T cell activation, effectively preventing allograft rejection. 1 However, the antirejection effects come at the expense of impaired T cell-mediated protective immunity 2 and numerous off-target side effects. 3 As such, efforts have been made to replace CNIs with a maintenance regimen with greater specificity for inhibiting alloreactive T cell-mediated immunity.
Belatacept, a cytotoxic T-lymphocyte-associated protein 4 fusion protein, blocks CD28/B7 costimulation signals during the interaction between T cells and antigen-presenting cells. Belatacept has demonstrated efficacy in preventing T cell-mediated allograft rejection without causing significant off-target side effects. 4 However, patients treated with belatacept-based immunotherapy without lymphocyte-depletional induction therapy experience significantly higher acute rejection rates than patients treated with CNI-based immunosuppressive regimens, 5 a condition called costimulation blockade-resistant rejection (CoBRR). 6, 7 Lymphocyte depletion with alemtuzumab prior to kidney transplantation effectively reduces the risk of CoBRR. 8, 9 Indeed, depletional induction and belatacept/sirolimus-based regimens without CNIs or steroids uniquely alter the T cell immune profile by inducing a repertoire enriched for CD2 low CD28 + cells, which are permissive for costimulation blockade-mediated control of allospecific T cell activation. 12 Indeed, memory T cells with the ability to produce granzymes and activating cytokines express CD57, thereby increasing the risk of long-term kidney allograft dysfunction.
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In this report, we examine the T cell populations emerging following alemtuzumab-mediated depletion in the presence of belatacept to examine their phenotype as it relates to costimulation dependence. We compare them to nondepleted patients receiving standard tacrolimusbased immunosuppression, to identify differences that could influence the occurrence of CoBRR posttransplantation, or during conversion from conventional immunosuppression to belatacept. We find that lymphocyte depletion with alemtuzumab and the subsequent lymphocyte repopulation, creates a repertoire with a decreased frequency and absolute number of differentiated T cell phenotypes, including cells expressing CD57
+ . We also demonstrate an increased frequency of CD31-expressing cells during T cell repopulation characterized mainly as naive cells, suggesting a thymic origin. We further find that renal transplant recipients have higher levels of circulating IL-7 following depletion than under conventional circumstances, and that less-differentiated CD57 − T cells express higher levels of the IL-7 receptor alpha chain (IL-7Rα; CD127). Because IL-7 is a critical mediator of homeostatic proliferation, 14 we posit that CD57 − T cells have a proliferative advantage during postdepletional lymphocyte reconstitution.
These findings identify a mechanistic explanation for the decreased frequency and absolute cell number of CD57 + T cells following lymphocyte depletion-induced repopulation. We hypothesize that the favorable clinical performance of belatacept following depletional induction therapy is due in part to reconstitution of a costimulationsensitive CD57 − T cell repertoire. Immunosuppression consisted of alemtuzumab induction followed by maintenance immunosuppressive therapy with belatacept and sirolimus, as reported previously. 
| MATERIALS AND METHODS

| Patients, immunosuppression, and follow-up
| Reagents and monoclonal antibodies
Monoclonal antibodies (mAbs) anti-CD3-Alexa-700, anti-CD3-PerCP, 
| Cells and flow cytometry
Absolute lymphocyte subsets were determined using BD Trucount tubes (BD Biosciences) according to the manufacturer's protocol.
Briefly, 50 μl of blood was added into a Trucount tube and incubated with mAbs specific to CD3, CD4, CD8, CD16, CD20, CD45, and CD56 for 15 minutes followed by incubation with Lysing Solution (Invitrogen) for 10 minutes. Peripheral blood mononuclear cells (PBMCs) were isolated from blood collected before and after transplantation by Ficoll density gradient centrifugation. Cells were resuspended in phosphate-buffered saline containing 1% fetal bovine serum. A minimum of 10 5 PBMCs were surface-stained with mAbs directed for CD3, CD4, CD8, CD57, PD1, CD45RA, CCR7, and IL-7Rα and analyzed using flow cytometry (BD Biosciences LSR II). Data analysis was performed using FlowJo software (Tree Star, San Carlos, CA). 
PD1
-subset skewed significantly toward naive cells during homeostatic reconstitution. *P < .05, *** P < .001, **** P < .0001
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| Measurement of serum IL-7
To determine the serum IL-7 levels during T cell repopulation after alemtuzumab induction, a standard ELISA was performed on serial serum samples in duplicate using human IL-7 kit according to the manufacturer's protocol. Serum samples longitudinally collected from patients treated with conventional maintenance immunosuppressive regimen were used as a reference comparator. Memorial Institute-1640 medium containing 20% human AB serum with or without 50 ng/mL recombinant IL-7 at 37°C for 10 days. Cells were collected and surface-stained with mAb directed to CD3, CD4, CD8, and IL-7Rα for 15 minutes. Cells were analyzed using flow cytometry, and the data analysis was performed using FlowJo software.
| Purification of CD57
| Statistical analysis
One-way analysis of variance (ANOVA) with posttesting for linear trend was performed to compare variables pre-and posttransplantation. 
| RESULTS
| Profound lymphocyte depletion by alemtuzumab induction and prevention of acute allograft rejection
As reported previously, profound lymphocyte depletion was achieved immediately following alemtuzumab therapy followed by slow CD4 + and CD8 + cell reconstitution and a relatively rapid B cell repopulation. Figure 1A ). This is consistent with previous observations in patients treated with depletional induction. 16 During the first month, there was relatively little change in cell count, attributed to the residual effects of alemtuzumab. However, as repopulation proceeded, the new repertoire progressively became more naive, returning to a baseline percentage distribution within 3 months, and thereafter developing a progressively more naive expression pattern.
Despite the marked shift toward a naive phenotype, the absolute 
CD57
-PD1 + subsets postalemtuzumab induction. The frequency and absolute number of these subsets decreased significantly below baseline levels after transient elevation during early reconstitution, and were phenotypically TEM and TEMRA cells prior to transplantation. A significant reduction of TEM subset and increased frequency for T naive subset during CD57 -PD1 + cell repopulation was observed
We then longitudinally evaluated the phenotype of T cell subsets of 10 patients treated with tacrolimus, mycophenolate mofetil, and prednisone. As shown in Figure 3A , neither CD4 + nor CD8 + cells demonstrated a notable change in the frequency for CD57 + and PD1 + cells. Furthermore, the naive and memory phenotypes of these T cell subsets with or without CD57 and/or PD1 expression remained unchanged posttransplantation when compared with pretransplantation baseline levels ( Figure 3B ). were analyzed based on the surface CD31 expression, a marker of recent thymic emigrants. 17 As shown in Figure 5 , the large fraction of CD4 + cells was CD31 − cells before depletional induction. However, following alemtuzumab induction, the repertoire was enriched for CD31-expressing CD4 + cells, and these CD4 + CD31 + cells were largely naive ( Figure S1 ). Unlike CD4 + cells, the CD8 (Figure S1 ).
| Reconstituted
| Alemtuzumab induction combined with belatacept/sirolimus therapy induces IL-7 production during T cell homeostatic reconstitution
Patients treated with alemtuzumab induction and belatacept/sirolimus immunosuppression repopulated predominantly with IL-7Rα expressing CD57 − PD1 − cells, skewing toward the naive phenotype. Serum samples longitudinally collected from these patients were analyzed by ELISA to detect IL-7 levels. As shown in Figure 6A , serum IL-7 was barely detectable prior to transplantation and became significantly elevated for 12 months (P = .0312) postalemtuzumab induction, followed by returning to baseline levels 24 months posttransplantation.
In contrast, patients treated with conventional maintenance immunosuppressive regimen without depletional induction did not demonstrate elevation of serum IL-7 after transplantation ( Figure 6B ).
| IL-7 induces CD57 − T cell proliferation and expansion
Homeostasis of T cells is critical in maintaining a normal size T cell pool or restoring T cell numbers by T cell expansion postdepletion. We dem- 
| DISCUSSION
CoBRR occurs in patients treated with nondepletional induction and belatacept-based maintenance immunosuppression prior to kidney transplantation. 5 The activation of allospecific memory T cells, including CD57 + T cells and other cells that through differentiation have reduced requirements for CD28-mediated costimulation, is thought to play a critical role in initiating CoBRR. 6, 7, 12 We recently demonstrated that a novel immunosuppression regimen of alemtuzumab induction followed by maintenance immunotherapy with belatacept and sirolimus effectively prevents CoBRR and enables some patients at low immunological risk to be weaned from sirolimus and maintain excellent graft function with belatacept monotherapy, a clear definition of costimulation-sensitive immunosuppression. 10 We have therefore investigated the T cell phenotype and function in these patients during the period of lymphocyte reconstitution following profound lymphocyte depletion, a period with significant opportunity to alter the immune repertoire. 17 We find that alemtuzumab induction results in substantial repertoire changes that make these recipients more responsive to belatacept-based regimens. These changes are not seen in patients treated with a conventional nondepletional regimen. These data speak both to the mechanisms involved in depletion-induced costimulation sensitivity, as well as the potential mechanisms of As relates to this depletional induction-based regimen, we hypothesize that the selective expansion of naive cells in these patients is driven at least in part by an IL-7R-mediated signaling mechanism, an important signaling pathway that has not been investigated in patients treated with lymphocyte-depletion induction. In this study, we find that patients treated with alemtuzumab followed by belatacept and sirolimus have increased serum IL-7 levels during homeostatic reconstitution. Previous studies have also observed a significant elevation of IL-7 production following lymphopenia. There are several limitations that conscribe this analysis. Although we have described longitudinal changes seen in the repertoire of patients treated with a novel alemtuzumab and belatacept-based regimen, we cannot ascribe the changes specifically to any particular aspect of this regimen. Given the stark departure of the trial regimen from the standard of care, a true control group for attribution of the characteristics observed would require controls for depletion, mode of depletion, CNI presence, and numerous other aspects of the regimen that distinguish it from more conventional therapies. Nevertheless, the repertoire changes we observed were not observed in nondepleted, CNI-treated patients, and the make-up of the repertoire in these conventionally treated patients did not skew toward a naive phenotype. This suggests that many patients on a nondepletional, CNI-based regimen may have a repertoire that is less conducive to belatacept treatment than those in our trial, and we believe this deserves attention when considering belatacept conversion.
Overall, the present data characterize aspects of the dynamics, functional responses, and expansion mechanisms of naive and differentiated T cells during homeostatic reconstitution in the context of kidney transplantation using alemtuzumab induction followed by belatacept/sirolimus-based immunosuppression. We find that this regimen results in the preferential homeostatic proliferation of naive IL-7Rα-expressing CD57 − T cells relative to IL-7Rα − CD57 + T cells. In contrast, patients receiving nondepletional induction and standard CNI-based immunosuppression do not significantly alter the relative frequency of these T cell subsets. We also find homeostatic expansion of naive CD4 + cells via thymic output. From our results, we propose that the reduction in CD57 + T cells seen following lymphocyte-depleting therapy is at least in part the result of selective expansion of CD57 − naive T cells during repopulation mediated by IL-7/IL-7R interactions. Overall, our findings reveal a potential explanation for the salutary effects of lymphocyte depletion in the setting of belatacept therapy in renal transplant patients, and provide insights to guide the development of subsequent CoB-based trials.
